Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.


HHS - 1918 - Office of AIDS Research Advisory Council - Statutory (Congress Created)
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameOffice of AIDS Research Advisory CouncilAgency NameDepartment of Health and Human Services
Fiscal Year2020Committee Number1918
Original Establishment Date6/27/1994Committee StatusChartered
Actual Termination Date Committee URLhttps://www.oar.nih.gov/hiv-policy-and-research...
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*30
Current Charter Date6/27/2020Designated Fed Officer Position Title*Supervisory Health Science Administrator
Date Of Renewal Charter6/27/2022Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Mary
Exempt From Renewal*NoDesignated Federal Officer Middle NameT
Specific Termination AuthorityDesignated Federal Officer Last Name*Glenshaw
Establishment Authority*Statutory (Congress Created)Designated Federal Officer SuffixPh.D.
Specific Establishment Authority*42 USC 300cc-40aDesignated Federal Officer Phone*(240) 669-2958
Effective Date Of Authority*6/10/1993Designated Federal Officer Fax*240-461-2055
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*mary.glenshaw@nih.gov
Committee Type*Continuing
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Office of AIDS Research Advisory Council (OARAC) is composed of highly qualified individuals who possess scientific expertise in HIV/AIDS research and a public commitment to advance the HIV/AIDS scientific agenda. The Council provides a breadth and balance of specialized knowledge necessary to advise the Director of the Office of AIDS Research (OAR) and the Director of the National Institutes of Health. The NIH Revitalization Act of 1993 called for the establishment of OARAC to provide advice on planning, coordination, and evaluating AIDS research supported by the NIH and to advise on the awarding of funds from the OAR Discretionary Fund, now referred to as the OAR Strategic Fund and the OAR Innovation Fund. The OAR depends heavily on the Council's advice in the extensive process of reviewing all NIH AIDS research and developing long-term research plans.
To accomplish this, briefing sessions on specific topics that are timely and of relevance were presented during FY2020 to update the OARAC. Updates included information on the relationship between drug use and addiction related HIV/AIDS research activities and cost sharing opportunities, particularly among populations who use drugs; information regarding the NIH Strategic Plan for HIV and HIV-Related Research; information from the Presidential Advisory Council on HIV/AIDS (PACHA); information on the NIH Tribal Research Office; information on the Ending the HIV Epidemic (EHE) research and initiatives; interagency discussion panel on EHE with leadership; data modeling to help improve HIV patient outcomes related to age and multimorbidity, optimizing the use of novel diagnostic tools to improve treatment outcomes among those on ART: and the role of simulation models to improve care for adolescents and young adults affected by HIV. Information was also presented regarding Interim Guidance for COVID-19 and Persons with HIV; discussions from the OAR Task Force on COVID-19 including HIV research recovery planning and efforts during and after the COVID-19 pandemic. In addition, each of the 3 FY20 meetings included timely information from the five HIV guidelines working groups under OARAC: Adult/Adolescent ARV, Adult/Adolescent Opportunistic Infection; Perinatal; Pediatric ARV and Pediatric Opportunistic infection, as well as the four NIH advisory councils that report to OARAC: the AIDS Research Advisory Committee, the National Advisory Mental Health Council, the National Advisory Council on Drug Abuse, and the National Cancer Advisory Board.
How is membership balanced?*The OARAC is composed of eighteen authorized members, twelve of whom are authorities in the fields of molecular biology, immunology, virology, neurology, pediatrics, vaccine development, antiviral development, clinical care, animal model research, retrovirology, structural biology, infectious disease, epidemiology, mental health, and substance abuse/addictions sciences. Six public members have expertise in public policy, health policy, economics, and management.
How frequent & relevant are cmte mtgs?*The OARAC meets approximately three times a year and provides advice on a continuing basis on the direction of the NIH AIDS research program, the development and annual review of a comprehensive plan for the conduct and support of all AIDS activities of the agencies of NIH, including direct involvement in budget projections for carrying out the plan which includes an estimate of the number and type of personnel needed for OAR. The Committee conducted three meetings on the following dates: 10/28/2019, 02/27/2020 and 06/25/2020.
Why advice can't be obtained elsewhere?*The committee and membership requirements are specifically addressed in statute. AIDS research is conducted throughout the NIH, which includes 23 Institutes and Centers, and 3 NIH OD Offices. The OARAC is the only council with advisory responsibilities applicable to the entire NIH AIDS research program. Therefore, it is essential to the coordination of the NIH AIDS scientific effort and research direction of the agency's AIDS programs.
Why close or partially close meetings?There were no closed or partially closed meetings in FY 2020.
Recommendation RemarksThere were no formal, substantive committee reports made to the Agency, the President, or the Congress in FY 2020.

General Information: The Committee charter specifies not more than 18 members and at least 11 non-voting ex officio members, currently there are 18 members and 12 ex officio members.

Members: Members Dazon Dixon-Diallo, Lynne Mofenson, Scott Rhodes, and Charles Wira were administratively extended until 3/28/2020 while new members are completing the appointment process.

Dr. Ingrid Bassett, Dr. John Chin, Dr. Jennifer Kates and Dr. William Powederly were all administratively extended until 3/29/2021 pending their replacements.

Ex Officio member Dr. Maureen Goodenow was inadvertently omitted on the 2019 ACR report, she has been included on this 2020 report.

Member Jennifer Kates was re-assigned from regular member to committee Chair on the 2019 Slate.

In 2019-2020 the Office of the General Counsel reviewed the committee charter and determined that Roy Gulick, a non-Fed who was chair of the guidelines working group, was incorrectly reported as an ex officio. He has been removed from this report.

Five Ex Officio members (Chaisson, Raab-Traub, Chang, Greenberg, and del Rio) are paid by their other appointed committee as Special Government Employees. These members serve on OARAC as required by the Charter as representatives of the other specific Council they are members of.

The Daily salary costs have been estimated for Federal Ex Officio members of this committee. The dollar figure represents a portion of their salary. No funds have been transferred between the committee and the agency. No additional funds are paid to Federal employees due to membership on this committee.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*No
Outcome Trust In GovernmentNoAction Reallocate ResourcesNo
Outcome Major Policy ChangesYesAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingYesAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionNoAction CommentThe Committee makes recommendations to the federal staff on the planning, coordination, and evaluation of research and other activities in respect to AIDS conducted or supported by the NIH. OARAC also advises the Secretary of Health and Human Services, the Assistant Secretary for Health, the Director of NIH, and the Director of OAR, on AIDS research programs, the development and annual review of the comprehensive plan for the conduct and support of all AIDS activities of the agencies of NIH, including research policies and priorities, and the coordination of domestic and international NIH AIDS efforts.
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentNANumber Of Grants Recommended0
Cost Savings*NoneDollar Value Of Grants Recommended$0.00
Cost Savings CommentNIH supported basic and clinical research accomplishments which often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.Grants Review CommentNA
Number Of Recommendations*168Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentBriefing sessions on specific topics that are timely and of relevance were presented during FY2020 to update the OARAC with several recommendations:
October 2019 - Recommendation for (1) description of clinical HIV guidelines review processes across the five OARAC working groups; (2) a more rapid update of the Adult and Adolescent ARV Guidelines regarding treatment as prevention or U=U, noting the urgency felt by the community on this issue. OARAC moved to emphasize the urgency of this issue and encouraged the panel to publish its update in December 2019, rather than January 2020, and requested a more detailed explanation of the update process at a future meeting. The Guidelines representatives agreed to incorporate these recommendations in their plans.
February 2020- Recommendation for (1) further coordination with other international groups in addition to PEPFAR; (2) additional linkage of OAR efforts with efforts related to the ongoing opioid epidemic; (3) reporting at a future OARAC meeting from a committee working to include pregnant women in clinical trials; (4) consideration of opportunities to further understand the new coronavirus emerging in late 2019 in the context of HIV and access to treatment during disasters; and (5) adding K awards or other training related components to the Ending the HIV Epidemic initiative
June 2020- Recommendation for (1) linking the Ending the HIV Epidemic initiative activities to COVID-19-related activities, particularly because the many years of investment in HIV research infrastructure are the reason this infrastructure is available to conduct COVID-19 research; (2) inclusion of community members in the discussions of COVID-19 and HIV trial designs, reviews, and protocols; (3) exploration of the collateral damage of COVID-19 on the HIV infrastructure, including how well people are maintaining their treatment and how they are adapting to the new environment; (4) recommend exploration of the effects of age on both the course of COVID-19 among persons with HIV and interactions of multiple medications; (5) quantification of the impact of this the COVID-19 epidemic on other major health issues, especially in resource-constrained settings; (6) ensuring that NIH-supported HIV research remains possible is critical to drive research in academia; (7) recommend that extending the length of grants should be considered given research delays from the COVID-19 pandemic.
Access Agency WebsiteYes
% of Recs Fully Implemented*0.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentDue to the complexity of the recommendations made by this committee, staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*0.00%Access PublicationsNo
% of Recs Partially Implemented CommentDue to the complexity of the recommendations made by this committee, staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback Comment*Minutes, oral presentations, and written reports.Narrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The NIH mission is to uncover new knowledge that will lead to better health for everyone. All of the NIH Institutes and Centers sponsor AIDS research. The OARAC is the only council with advisory responsibilities applicable to the entire NIH AIDS research program. Therefore, it is essential to the coordination of the NIH AIDS scientific effort and research direction of the agency’s AIDS programs. At each meeting, the OARAC receives an update on the activities of the five Working Groups. These Working Groups are sponsored under the auspices of the OARAC and are responsible for the development of state-of-the-science federal guidelines for the medical management of HIV disease and its associated coinfections and opportunistic infections in adults, adolescents, and children.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$6,400.00Est Payments to Non-Fed Members Next FY*$6,400.00
Payments to Federal Members*$7,860.00Est. Payments to Fed Members Next FY*$7,860.00
Payments to Federal Staff*$238,467.00Estimated Payments to Federal Staff*$244,667.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$7,248.00Est Travel Reimb Non-Fed Members nextFY*$7,367.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$128,383.00Est. Other Costs Next FY*$129,785.00
Total Costs$388,358.00Est. Total Next FY*$396,079.00
Federal Staff Support (FTE)*1.40Est. Fed Staff Support Next FY*1.40
Cost RemarksCosts are higher that projected in FY19 due to Federal staff costs increases and logistical support increases. Due to the COVID-19 pandemic, FY2020 meetings held after March 12, 2020 were virtual only, which reduced some committee operational costs. Daily salary costs have been estimated for Federal Ex Officio members of this committee. The dollar figure represents a portion of their annual salary. No funds have been transferred between the committee and the agency. No additional funds are paid to Federal employees due to membership on this committee.Est Cost RemarksIf in person meetings resume, committee costs for FY2021 may be higher.
Hide Section - Interest Areas

Interest Areas

Category
Area
Health
Health Care
Medicine
Health and Health Research
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-036508Office of AIDS Research Advisory Council2019
 COM-034713Office of AIDS Research Advisory Council2018
 COM-001617Office of AIDS Research Advisory Council2017
 COM-002405Office of AIDS Research Advisory Council2016
 COM-003773Office of AIDS Research Advisory Council2015
 COM-004720Office of AIDS Research Advisory Council2014
 COM-006285Office of AIDS Research Advisory Council2013
 COM-006613Office of AIDS Research Advisory Council2012
 COM-008359Office of AIDS Research Advisory Council2011
 COM-008741Office of AIDS Research Advisory Council2010
 COM-010350Office of AIDS Research Advisory Council2009
 COM-010719Office of AIDS Research Advisory Council2008
 COM-011868Office of AIDS Research Advisory Council2007
 COM-012831Office of AIDS Research Advisory Council2006
 COM-014043Office of AIDS Research Advisory Council2005
 COM-014490Office of AIDS Research Advisory Council2004
 COM-015920Office of AIDS Research Advisory Council2003
 COM-016476Office of AIDS Research Advisory Council2002
 COM-017990Office of AIDS Research Advisory Council2001
 COM-018699Office of AIDS Research Advisory Council2000
 COM-019819Office of AIDS Research Advisory Council1999
 COM-020404Office of AIDS Research Advisory Council1998
 COM-021591Office of AIDS Research Advisory Council1997